Business Context and Reporting Period
This Form 8-K reports on the results of the 2025 Annual Meeting of Stockholders held by TherapeuticsMD, Inc. on December 15, 2025. The meeting addressed corporate governance, executive compensation, auditor ratification, and a capital structure amendment.
Key Financial Metrics
The filing text does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the outcomes of shareholder votes.
Material Changes and Voting Results
At the record date of October 20, 2025, there were 11,574,362 shares outstanding. A quorum was established with 6,842,247 shares represented. The following material actions were approved:
- Board Elections: All four nominees (Tommy G. Thompson, Cooper C. Collins, Gail K. Naughton, Ph.D., and Justin Roberts) were elected to the Board of Directors.
- Executive Compensation: Stockholders approved the non-binding advisory vote on executive compensation for the fiscal year ended December 31, 2024.
- Voting Frequency: Stockholders approved a 1-year frequency for future non-binding advisory votes on executive compensation.
- Auditor Ratification: The appointment of Berkowitz Pollack Brant Advisors + CPAs, LLP as the independent auditor for the fiscal year ending December 31, 2025, was ratified.
- Capital Structure: Stockholders approved an amendment to the Articles of Incorporation to increase the number of authorized common shares to 640,000,000.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, operational outlook, or specific risk factors. The document serves strictly as a disclosure of the voting results.
Investor Verification Checklist
- Verify the impact of the increased authorized share count (640,000,000 shares) on potential future dilution.
- Review the Definitive Proxy Statement (Schedule 14A) filed on November 3, 2025, for detailed biographies of the newly elected directors and executive compensation specifics.
- Confirm the independence and qualifications of the newly ratified auditor, Berkowitz Pollack Brant Advisors + CPAs, LLP.
- Monitor subsequent filings for any issuance of shares from the newly authorized pool.